Open AccessCommonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children’s Oncology Group
Author(s) -
Janice S. Withycombe,
Aimee Carlson,
C. Lynn Coleman,
Sharon Leslie,
Micah Skeens,
Hanna Tseitlin,
Elizabeth A. Duffy
Publication year - 2020
Publication title -
journal of pediatric oncology nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 50
eISSN - 1532-8457
pISSN - 1043-4542
DOI - 10.1177/1043454220966590
Subject(s) - medicine , immunotherapy , oncology , grading (engineering) , adverse effect , blinatumomab , rituximab , intensive care medicine , cancer , lymphoma , lymphoblastic leukemia , civil engineering , leukemia , engineering
Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice.